The use of preventive measures and self-treatment for travelers' diarrhea is routine in regions where the occurrence of diarrhea is predictably high. People traveling to these areas who do not ...
In May 2004, the US FDA approved rifaximin for the treatment of travelers' diarrhea caused by noninvasive strains of diarrheogenic E. coli. In view of the fact that the overall treatment failure ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback